Empirica: Building a new model for brain cancer

Empirica is developing antibody therapeutics based on the biology of recurrence

Empirica is developing antibody-based therapies for glioblastoma multiforme using a mouse model built to mimic the biology of recurrent brain cancer, rather than that of primary tumors. Its lead candidate is a CAR T cell therapy that targets a biomarker of cancer stem cells.

Empirica Therapeutics Inc. CEO Sheila Singh said she sought to develop a better preclinical model for

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers